GFM
NTLA icon

GF Fund Management’s Intellia Therapeutics NTLA Stock Holding History

GF Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2K Buy
2,587
+312
+14% +$3.97K ﹤0.01% 449
2025
Q4 		$20.5K Sell
2,275
-35
-2% -$482 ﹤0.01% 508
2025
Q3 		$39.9K Sell
2,310
-298
-11% -$3.67K ﹤0.01% 418
2025
Q2 		$24.5K Hold
2,608
– – ﹤0.01% 481
2025
Q1 		$18.5K Buy
2,608
+469
+22% +$4.74K ﹤0.01% 510
2024
Q4 		$24.9K Buy
+2,139
New +$33.4K ﹤0.01% 453

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GF Fund Management's NTLA Position: Q1 2026 in Review

GF Fund Management increased its Intellia Therapeutics (NTLA) stake by 14% in Q1 2026, buying an estimated $3.97K and bringing the position to 2,587 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #449.

GF Fund Management first reported a position in NTLA in Q4 2024 and has held it in 6 quarters since. The position peaked at $39.9K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • GF Fund Management held 2,587 shares of Intellia Therapeutics worth $33.2K as of Q1 2026.
  • GF Fund Management bought 312 Intellia Therapeutics shares in Q1 2026, an estimated $3.97K.
  • Intellia Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #449 holding.
  • GF Fund Management first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Intellia Therapeutics position peaked at $39.9K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.